U.S. Markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
224.81+4.50 (+2.04%)
At close: 1:00PM EST

224.81 0.00 (0.00%)
After hours: 1:13PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close220.31
Open221.41
Bid224.01 x 1000
Ask224.69 x 900
Day's Range221.39 - 226.21
52 Week Range177.05 - 264.97
Volume1,592,977
Avg. Volume2,837,770
Market Cap130.877B
Beta (5Y Monthly)0.81
PE Ratio (TTM)18.13
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield6.40 (2.90%)
Ex-Dividend DateNov 13, 2020
1y Target EstN/A
  • Amgen To Present At The Evercore ISI Virtual HealthCONx Conference
    PR Newswire

    Amgen To Present At The Evercore ISI Virtual HealthCONx Conference

    Amgen (NASDAQ:AMGN) will present at the Evercore ISI Virtual HealthCONx Conference at 1:50 p.m. ET on Tuesday, Dec. 1, 2020. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.

  • Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics
    PR Newswire

    Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics

    Amgen (NASDAQ:AMGN) today announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the development and commercialization rights for omecamtiv mecarbil and AMG 594. Omecamtiv mecarbil, an investigational selective cardiac myosin activator, was studied in GALACTIC-HF, a Phase 3 clinical trial in patients with chronic heart failure with reduced ejection fraction (HFrEF), and AMG 594, a novel mechanism selective cardiac troponin activator, is in Phase 1 development for HFrEF and other types of heart failure.

  • Amgen To Present At The Jefferies Virtual London Healthcare Conference
    PR Newswire

    Amgen To Present At The Jefferies Virtual London Healthcare Conference

    Amgen (NASDAQ:AMGN) will present at the Jefferies Virtual London Healthcare Conference at 12:00 p.m. ET on Wednesday, Nov. 18, 2020. Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.